MedPath

Catheter Directed Therapy in Intermediate Risk Pulmonary Embolism Patients

Early Phase 1
Not yet recruiting
Conditions
Pulmonary Embolism Subacute Massive
Interventions
Device: Suction embolectomy by the Penumbra Indigo aspiration system
Registration Number
NCT05612854
Lead Sponsor
Assiut University
Brief Summary

Aim of the work:

1. To compare conventional medical therapy versus catheter-directed therapy in intermediate high risk acute pulmonary embolism.

2. To define predictors of progression from intermediate to high-risk in medically-treated patients for ideal timing for intervention.

Detailed Description

Based on history, physical examination, surface 12-lead ECG, bed-side echocardiography, patients with a high probability of acute pulmonary embolism are selected and subjected to CT pulmonary angiography to confirm the diagnosis and calculate the pulmonary artery obstruction score.

Routine labs are withdrawn, including cardiac troponin.Methods:

Detailed TTE will be done with emphasis on the following indicators of RV strain and/or dysfunction:

1. Echocardiography findings that are indicative of RV dysfunction

* tricuspid annular plane systolic excursion (TAPSE)

* S' Velocity

* the McConnell's sign

2. RV dilation

3. interventricular septal flattening.

4. elevated right ventricular pressures

5. plethoric inferior vena cava

6. tricuspid regurgitation

7. Direct visualization of thromboembolic in the RT heart and PA

8. RV stroke volume measured by RVOT VTI.

9. LV stroke volume measured by LVOT VTI Intermediate-high risk patient will be identified (based on the calculated pulmonary embolism severity index, RV dysfunction on TTE and/or CT, cardiac troponin), and then randomized to either receiving conventional medical treatment or catheter-directed interventional therapy if the patient consents.

7. Catheter directed therapy

A. Mechanical embolectomy:

Mechanical fragmentation will be done using a 6 F pigtail catheter inserted inside the thrombus guided by the CTPA images.

Hydro-mechanical defragmentation (HMD) is one of the CDT modalities for high-risk PE patients, in which rapid pigtail rotation is combined with heparinized saline injection for thrombus fragmentation.(4)

B. Suction embolectomy:

Suction embolectomy was one of the earliest techniques for transcatheter treatment of PE, and was introduced by Greenfield et al, using a 12-Fr catheter with a cup on its distal end. Suction was applied manually to the catheter hub with a large syringe. (13) The Penumbra Indigo aspiration system (Penumbra Inc., Alameda, CA, USA) that will be used, is an 8-Fr device and its associated tubing, pump, and separator, has the flexibility for placement in segmental branches of the pulmonary arteries. The Indigo aspiration system is indicated for use in the peripheral arterial system and the pulmonary arteries, receiving U.S. Food and Drug Administration 510(k) clearance for PE in December 2019.(14)

C. Catheter directed thrombolysis:

Catheter-directed thrombolysis allows delivery of the thrombolytic agent directly to the area of highest embolic burden via a catheter.

Intermediate-high risk patient will be identified (based on the calculated pulmonary embolism severity index, RV dysfunction on TTE and/or CT, cardiac troponin), and then randomized to either receiving conventional medical treatment or catheter-directed interventional therapy if the patient consents.

Recruitment & Eligibility

Status
NOT_YET_RECRUITING
Sex
All
Target Recruitment
200
Inclusion Criteria
  • Acute pulmonary embolism patients (confirmed by CT pulmonary angiography [CTPA])
  • symptoms started within 15 days of enrollment
  • intermediate-high risk pulmonary embolism patients , i.e., who have all of the following risk indicators combined :(2) i.Pulmonary Embolism Severity Index (PESI) class III-V or sPESI ≥1, ii.AND RV dysfunction on TTE or CTPA, iii.AND elevated cardiac troponin levels
  • with none of the following high-risk presentations: cardiac arrest, systolic blood pressure <90 mmHg, or vasopressors required to achieve a BP ≥90 mmHg despite an adequate filling status, or end-organ hypoperfusion.
Exclusion Criteria
  • high risk patients who are hemodynamically unstable (cardiogenic shock, SBP <90 mmHg, or use of intotropic support).
  • low risk patients with no RV dysfunction.
  • Patients with history of CTEPH (or previous acute PE)
  • Patients known to have other pulmonary hypertension, apart from group IV (CTEPH).
  • Patients with sever kidney injury (eGFR <30 mg/dl/1.7m2).

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
catheter directed therapy group in intermediate risk pulmonary embolism patientsSuction embolectomy by the Penumbra Indigo aspiration systemin this arm, intermediated risk pulmonary embolism patients is treated by intervention in the form of: * A. Mechanical embolectomy: by hydromechanical defragmentation by pigta * B. Suction embolectomy: using The Penumbra Indigo aspiration system * C. Catheter directed thrombolysis:
medical therapy group in intermediate risk pulmonary embolism patientsSuction embolectomy by the Penumbra Indigo aspiration systemin this arm, intermediated risk pulmonary embolism patients is treated by routine anticoagulation only.
Primary Outcome Measures
NameTimeMethod
1.comparison between conventional medical therapy and catheter-directed therapy in intermediate high risk acute pulmonary embolism patientsup to 2 years

comparison in intermediate high risk acute pulmonary embolism patients between conventional medical therapy and catheter-directed therapy as regarding safety and efficacy of the therapy by CT pulmonary angiography to asses embolus size and Pulmonary artery obstruction index

Secondary Outcome Measures
NameTimeMethod
predictors of progression from intermediate to high-risk acute pulmonary embolism patientsup to 2 years

identifying predictors for ideal timing for intervention in intermediate risk pulmonary embolism patients who are medically-treated by new echocardiographic parameters (LVOT velocity time integral and RVOT velocity time integral)

© Copyright 2025. All Rights Reserved by MedPath